JP2016507066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507066A5 JP2016507066A5 JP2015557128A JP2015557128A JP2016507066A5 JP 2016507066 A5 JP2016507066 A5 JP 2016507066A5 JP 2015557128 A JP2015557128 A JP 2015557128A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2016507066 A5 JP2016507066 A5 JP 2016507066A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- subject
- biological sample
- polypeptide
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims description 138
- 239000012472 biological sample Substances 0.000 claims description 128
- 238000000034 method Methods 0.000 claims description 109
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 103
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 97
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 97
- 229920001184 polypeptide Polymers 0.000 claims description 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 60
- 239000006228 supernatant Substances 0.000 claims description 49
- 230000004083 survival effect Effects 0.000 claims description 48
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 47
- 210000002966 serum Anatomy 0.000 claims description 46
- 239000000523 sample Substances 0.000 claims description 45
- 238000003556 assay Methods 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 41
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 41
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 40
- 238000003018 immunoassay Methods 0.000 claims description 36
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 35
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 35
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 34
- 210000001185 bone marrow Anatomy 0.000 claims description 32
- 210000005087 mononuclear cell Anatomy 0.000 claims description 32
- 238000002965 ELISA Methods 0.000 claims description 24
- 238000003127 radioimmunoassay Methods 0.000 claims description 24
- 208000034578 Multiple myelomas Diseases 0.000 claims description 19
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 17
- 238000012286 ELISA Assay Methods 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000002055 immunohistochemical effect Effects 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 230000002250 progressing effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762753P | 2013-02-08 | 2013-02-08 | |
| US61/762,753 | 2013-02-08 | ||
| PCT/US2014/015338 WO2014124280A1 (en) | 2013-02-08 | 2014-02-07 | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018090456A Division JP2018136344A (ja) | 2013-02-08 | 2018-05-09 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016507066A JP2016507066A (ja) | 2016-03-07 |
| JP2016507066A5 true JP2016507066A5 (enExample) | 2017-03-09 |
Family
ID=51300158
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557128A Withdrawn JP2016507066A (ja) | 2013-02-08 | 2014-02-07 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
| JP2018090456A Pending JP2018136344A (ja) | 2013-02-08 | 2018-05-09 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018090456A Pending JP2018136344A (ja) | 2013-02-08 | 2018-05-09 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10126301B2 (enExample) |
| EP (1) | EP2954330A4 (enExample) |
| JP (2) | JP2016507066A (enExample) |
| CA (1) | CA2900529A1 (enExample) |
| WO (1) | WO2014124280A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10126301B2 (en) | 2013-02-08 | 2018-11-13 | Institute For Myeloma & Bone Cancer Research | Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma |
| KR20180077193A (ko) * | 2015-10-30 | 2018-07-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 예후 방법 |
| ES2898329T3 (es) * | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| EP3458853B1 (en) | 2016-05-16 | 2022-09-07 | Onco Tracker, Inc. | Improved methods for monitoring immune status of a subject |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| WO2018160553A1 (en) * | 2017-02-28 | 2018-09-07 | Menarini Silicon Biosystems, Inc. | Improved kits and assays to detect circulating multiple myeloma cells from blood |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| ES2644580B2 (es) * | 2017-07-26 | 2018-06-04 | Universitat Politècnica De València | Procedimiento de diagnóstico de lupus eritematoso sistémico (les) |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN112639475A (zh) * | 2018-08-31 | 2021-04-09 | 豪夫迈·罗氏有限公司 | Dlbcl的预后指数中的胸苷激酶(tk-1) |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| JP2024515591A (ja) | 2021-04-08 | 2024-04-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｃｒに結合する多機能性分子およびその使用 |
| CN117305458B (zh) * | 2023-10-20 | 2024-06-21 | 四川省医学科学院·四川省人民医院 | TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒 |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| EP0937461B1 (en) | 1996-07-10 | 2005-07-06 | Meiji Dairies Corporation | Use of proteins from the mk family as hematopoietic factor |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| EP1389203B8 (en) | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
| AU2002339901A2 (en) | 2001-09-06 | 2003-03-24 | Biogen Idec Ma Inc. | Crystal structure of baff, and use thereof in drug design |
| AU2004220078A1 (en) | 2003-03-07 | 2004-09-23 | Xencor, Inc | BAFF mutants with at least one amino acid substitution and methods of their production |
| EP1826218B1 (en) | 2004-08-31 | 2014-01-01 | Kowa Company, Ltd. | Antihuman baff antibody |
| EP2332563A3 (en) | 2004-10-13 | 2013-03-13 | The Washington University | Use of BAFF to treat sepsis |
| US7947805B2 (en) | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
| AU2006298794B2 (en) * | 2005-09-26 | 2012-05-10 | Enzo Life Sciences, Inc. | Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients |
| WO2007053732A2 (en) | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| WO2007056288A2 (en) * | 2005-11-08 | 2007-05-18 | Biogen Idec Ma Inc. | Methods of evaluating baff |
| US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| AU2007248019B2 (en) | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| HUE029236T2 (en) | 2007-06-13 | 2017-02-28 | Incyte Holdings Corp | (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| SI3415531T1 (sl) * | 2011-05-27 | 2023-12-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - vezni proteini |
| ES2937015T3 (es) | 2012-11-01 | 2023-03-23 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Anticuerpo contra CD269 (BCMA) |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| US10126301B2 (en) | 2013-02-08 | 2018-11-13 | Institute For Myeloma & Bone Cancer Research | Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma |
| WO2015109286A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| KR102526945B1 (ko) | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| US20170224730A1 (en) | 2014-06-10 | 2017-08-10 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| SG11201704549UA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| WO2016149350A1 (en) | 2015-03-17 | 2016-09-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
| EP3662909A1 (en) | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| WO2017031104A1 (en) | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| KR20180077193A (ko) | 2015-10-30 | 2018-07-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 예후 방법 |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| EP3458853B1 (en) | 2016-05-16 | 2022-09-07 | Onco Tracker, Inc. | Improved methods for monitoring immune status of a subject |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2018085363A2 (en) | 2016-11-02 | 2018-05-11 | Berenson James Richard | Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| WO2019018603A2 (en) | 2017-07-19 | 2019-01-24 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| EP3873478A4 (en) | 2018-10-31 | 2022-08-10 | Oncotracker, Inc. | METHOD OF IMPROVING IMMUNE-BASED THERAPY |
-
2014
- 2014-02-07 US US14/766,694 patent/US10126301B2/en active Active
- 2014-02-07 JP JP2015557128A patent/JP2016507066A/ja not_active Withdrawn
- 2014-02-07 WO PCT/US2014/015338 patent/WO2014124280A1/en not_active Ceased
- 2014-02-07 EP EP14748765.6A patent/EP2954330A4/en not_active Withdrawn
- 2014-02-07 CA CA2900529A patent/CA2900529A1/en not_active Abandoned
-
2018
- 2018-05-09 JP JP2018090456A patent/JP2018136344A/ja active Pending
- 2018-09-28 US US16/146,300 patent/US12174189B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013210776B2 (en) | Biomarkers for gastric cancer and uses thereof | |
| Szczudlik et al. | Antititin antibody in early‐and late‐onset myasthenia gravis | |
| US9134326B2 (en) | Biomarkers for liver fibrosis | |
| WO2021076036A1 (en) | Apparatuses and methods for detection of pancreatic cancer | |
| JP2010513901A5 (enExample) | ||
| Li et al. | Anti-PLA2R antibodies in Chinese patients with membranous nephropathy | |
| JP2015517801A5 (enExample) | ||
| Kuuliala et al. | Constitutive STAT3 phosphorylation in circulating CD4+ T lymphocytes associates with disease activity and treatment response in recent-onset rheumatoid arthritis | |
| US8748352B2 (en) | Peptide and protein biomarkers for type 1 diabetes mellitus | |
| JP2017531801A5 (enExample) | ||
| RU2018103933A (ru) | Моноклональные антитела, с ориентировкой на антиген Р респираторно-синцитиального вируса человека, получаемые и секретируемые из клеточных гибридом, используемые для обнаружения и диагностики инфекции, вызываемой респираторно-синцитиальным вирусом | |
| Hou et al. | Lower serum and higher urine immunoglobulin G are associated with an increased severity of idiopathic membranous nephropathy | |
| Cui et al. | Future biomarkers for infection and inflammation in rheumatoid arthritis | |
| IL259029A (en) | A method for characterizing cell-specific tiny blisters | |
| JP5805518B2 (ja) | マルチプレックス大腸がんマーカーパネル | |
| JP2017524933A5 (enExample) | ||
| JP2014224759A5 (enExample) | ||
| WO2019117132A1 (ja) | がん免疫療法の予後予測のためのバイオマーカー | |
| US20170315119A1 (en) | Urinary biomarkers for sle and lupus nephritis | |
| WO2022184942A2 (en) | Biomarkers | |
| RU2017107273A (ru) | Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров | |
| CN111562390A (zh) | 一种神经精神性狼疮的诊断标志物及其检测试剂盒 | |
| Vase et al. | Proteomic profiling of pretreatment serum from HIV-infected patients identifies candidate markers predictive of lymphoma development | |
| WO2015048100A1 (en) | Biomarker for early neurodegeneration detection | |
| KR20130040294A (ko) | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 |